ClinicalTrials.gg
CompletedNCT03766685Updated Jul 14, 2025Results posted

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

A Phase 3 interventional study of Bimekizumab in Chronic Plaque Psoriasis and Moderate to Severe Chronic Plaque Psoriasis, sponsored by UCB Biopharma SRL. Completed at 39 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing bimekizumab in Psoriasis — 4 open to participants now, 5 under way, 3 of them phase 3. bimekizumab · Psoriasis.

Enrollment
10th of 20
172 · median 161
Started
2018
with 3 others
Phase 3
10 of 20
2 open now
Registered
10th of 20
by date
Lead sponsor
13 of 20
UCB Biopharma SRL

Among the 20 studies testing bimekizumab in Psoriasis, this one is the 10th largest by enrollment, is one of 4 that started in 2018, is one of 10 in phase 3, and was the 10th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 20 studies testing bimekizumab in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing bimekizumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the ability of subjects with moderate to severe chronic plaque psoriasis (PSO) to safely and effectively self-inject bimekizumab at study start and 8 weeks after training in self-injection technique using a prefilled safety syringe or an auto-injector.

03

Conditions studied

  • Chronic Plaque Psoriasis
  • Moderate to Severe Chronic Plaque Psoriasis

Browse trials for

Keywords

  • Bimekizumab
  • PSO
  • Psoriasis
  • Auto-Injector
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject fulfills all inclusion criteria for the PS0014 [NCT03598790] study
  • Subject is considered reliable and capable of adhering to the DV0002 protocol (eg, able to understand and complete questionnaires, willing to self-inject, able to use device according to the instructions for use (IFU), and able to adhere to the visit schedule) according to the judgment of the Investigator

Exclusion criteria

Exclusion Criteria:

  • Subjects are not permitted to enroll in DV0002 if any of the PS0014 [NCT03598790] study exclusion criteria are met
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
172 participants (actual)

Study arms

  • Experimental
    Bimekizumab-SS

    Subjects will receive assigned bimekizumab dose regimen using a prefilled safety syringe (SS).

    Drug: Bimekizumab

  • Experimental
    Bimekizumab-AI

    Subjects will receive assigned bimekizumab dose regimen using an auto-injector (AI).

    Drug: Bimekizumab

Interventions

  • Subjects will receive bimekizumab at pre-specified time-points.

    Also known as: UCB4940, BKZ

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-safety Syringe (SS)-1mL or the Bimekizumab-auto-injector (AI)-1mL at Week 8, After Training in Self-injection Technique

    Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-safety syringe (SS) or the bimekizumab-auto-injector (AI) which shows that the investigational medicinal product (IMP) was delivered completely (ie, container is empty), and - No Adverse Device Effects (ADEs) that would preclude continued use of the device for self-injection (ie, no serious ADEs (SADEs) and/or ADEs leading to withdrawal).

    Time frame: Week 8

  2. Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-2mL or the Bimekizumab-AI-2mL at Week 8, After Training in Self-injection Technique

    Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-SS or the bimekizumab-AI which shows that the IMP is delivered completely (ie, container is empty), and - No ADEs that would preclude continued use of the device for self-injection (ie, no serious ADEs (SADEs) and/or ADEs leading to withdrawal).

    Time frame: Week 8

Secondary outcomes

  1. Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-1mL or the Bimekizumab-AI-1mL at Baseline, After Training in Self-injection Technique

    Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-SS or the bimekizumab-AI which showed that the IMP was delivered completely (ie, container is empty), and - No ADEs that would preclude continued use of the device for self-injection (ie, no SADEs and/or ADEs leading to withdrawal).

    Time frame: Baseline (the first self-injection visit)

  2. Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-2mL or the Bimekizumab-AI-2mL at Baseline, After Training in Self-injection Technique

    Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-SS or the bimekizumab-AI which shows that the IMP is delivered completely (ie, container is empty), and - No ADEs that would preclude continued use of the device for self-injection (ie, no SADEs and/or ADEs leading to withdrawal).

    Time frame: Baseline (the first self-injection visit)

07

Results

Posted Aug 8, 2023

Participant flow

The study started to enroll study participants in December 2018 and concluded in September 2020. This study is a substudy to PS0014 (NCT03598790).

Participant flow — Overall Study
MilestoneBimekizumab-SS-1mL 320 mgBimekizumab-AI-1mL 320 mgBimekizumab-SS-2mL 320 mgBimekizumab-AI-2mL 320 mg
Started66681919
Completed65611918
Not completed1701
Withdrew: Lost to follow-up1100
Withdrew: Adverse event, not fatal0101
Withdrew: Withdrawal by subject0200
Withdrew: Protocol violation0100
Withdrew: Non-compliance0200

Outcome measures

PrimaryPercentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-safety Syringe (SS)-1mL or the Bimekizumab-auto-injector (AI)-1mL at Week 8, After Training in Self-injection Technique

Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-safety syringe (SS) or the bimekizumab-auto-injector (AI) which shows that the investigational medicinal product (IMP) was delivered completely (ie, container is empty), and - No Adverse Device Effects (ADEs) that would preclude continued use of the device for self-injection (ie, no serious ADEs (SADEs) and/or ADEs leading to withdrawal).

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-safety Syringe (SS)-1mL or the Bimekizumab-auto-injector (AI)-1mL at Week 8, After Training in Self-injection Technique
percentage of participantsBimekizumab-SS-1mL 320 mg (FAS-s-1mL)Bimekizumab -AI-1mL 320 mg (FAS-a-1mL)
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-safety Syringe (SS)-1mL or the Bimekizumab-auto-injector (AI)-1mL at Week 8, After Training in Self-injection Technique100 (95.4 to 100)100 (95.3 to 100)
PrimaryPercentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-2mL or the Bimekizumab-AI-2mL at Week 8, After Training in Self-injection Technique

Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-SS or the bimekizumab-AI which shows that the IMP is delivered completely (ie, container is empty), and - No ADEs that would preclude continued use of the device for self-injection (ie, no serious ADEs (SADEs) and/or ADEs leading to withdrawal).

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-2mL or the Bimekizumab-AI-2mL at Week 8, After Training in Self-injection Technique
percentage of participantsBimekizumab-SS-2mL 320 mg (FAS-s-2mL)Bimekizumab-AI-2mL 320 mg (FAS-a-2mL)
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-2mL or the Bimekizumab-AI-2mL at Week 8, After Training in Self-injection Technique100 (85.4 to 100)94.7 (77.4 to 99.7)
SecondaryPercentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-1mL or the Bimekizumab-AI-1mL at Baseline, After Training in Self-injection Technique

Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-SS or the bimekizumab-AI which showed that the IMP was delivered completely (ie, container is empty), and - No ADEs that would preclude continued use of the device for self-injection (ie, no SADEs and/or ADEs leading to withdrawal).

Time frame:
Baseline (the first self-injection visit)
Reported as:
Number · percentage of participants
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-1mL or the Bimekizumab-AI-1mL at Baseline, After Training in Self-injection Technique
percentage of participantsBimekizumab-SS-1mL 320 mg (FAS-s-1mL)Bimekizumab -AI-1mL 320 mg (FAS-a-1mL)
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-1mL or the Bimekizumab-AI-1mL at Baseline, After Training in Self-injection Technique100 (95.4 to 100)97.1 (91.0 to 99.5)
SecondaryPercentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-2mL or the Bimekizumab-AI-2mL at Baseline, After Training in Self-injection Technique

Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-SS or the bimekizumab-AI which shows that the IMP is delivered completely (ie, container is empty), and - No ADEs that would preclude continued use of the device for self-injection (ie, no SADEs and/or ADEs leading to withdrawal).

Time frame:
Baseline (the first self-injection visit)
Reported as:
Number · percentage of participants
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-2mL or the Bimekizumab-AI-2mL at Baseline, After Training in Self-injection Technique
percentage of participantsBimekizumab-SS-2mL 320 mg (FAS-s-2mL)Bimekizumab-AI-2mL 320 mg (FAS-a-2mL)
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-2mL or the Bimekizumab-AI-2mL at Baseline, After Training in Self-injection Technique100 (85.4 to 100)100 (85.4 to 100)

Adverse events

Collected over From Baseline up to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bimekizumab-SS-1mL 320 mg (SS-s-1mL)0/65 (0%)0/65 (0%)0/65 (0%)
Bimekizumab AI-1mL 320 mg (SS-a-1mL)0/68 (0%)0/68 (0%)0/68 (0%)
Bimekizumab-SS-2mL 320 mg (SS-s-2mL)0/19 (0%)0/19 (0%)1/19 (5.3%)
Bimekizumab-AI-2mL 320 mg (SS-a-2mL)0/19 (0%)0/19 (0%)1/19 (5.3%)
Most frequent other events
Most frequent other events
EventBimekizumab-SS-1mL 320 mg (SS-s-1mL)Bimekizumab AI-1mL 320 mg (SS-a-1mL)Bimekizumab-SS-2mL 320 mg (SS-s-2mL)Bimekizumab-AI-2mL 320 mg (SS-a-2mL)
Injection site reactionGeneral disorders0/650/681/190/19
Injection site painGeneral disorders0/650/680/191/19

Baseline characteristics

Baseline Characteristics refer to the Safety Set (SS) consisted of all study participants who received at least 1 dose of bimekizumab by the indicated self-injection investigational device presentation (bimekizumab-SS-1mL SS \[SS-s\], bimekizumab-AI-1mL SS \[SS-a\], bimekizumab-SS-2mL SS \[SS-s\] and bimekizumab-AI-2mL SS \[SS-a\]). One study participant included in the Enrolled Set did not self-inject at any time during the study and is therefore not included in the Safety Set (SS-s-1mL).

Age, Categorical
Age, Categorical(Participants)Bimekizumab-SS-1mL 320 mg (SS-s-1mL)Bimekizumab AI-1mL 320 mg (SS-a-1mL)Bimekizumab-SS-2mL 320 mg (SS-s-2mL)Bimekizumab-AI-2mL 320 mg (SS-a-2mL)Total Title
<=18 years11002
Between 18 and 65 years57591618150
>=65 years783119
Age, Continuous
Age, Continuous(years)Bimekizumab-SS-1mL 320 mg (SS-s-1mL)Bimekizumab AI-1mL 320 mg (SS-a-1mL)Bimekizumab-SS-2mL 320 mg (SS-s-2mL)Bimekizumab-AI-2mL 320 mg (SS-a-2mL)Total Title
Mean49.7 ± 13.446.8 ± 14.050.3 ± 15.843.0 ± 12.447.9 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)Bimekizumab-SS-1mL 320 mg (SS-s-1mL)Bimekizumab AI-1mL 320 mg (SS-a-1mL)Bimekizumab-SS-2mL 320 mg (SS-s-2mL)Bimekizumab-AI-2mL 320 mg (SS-a-2mL)Total Title
Female22199959
Male43491010112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bimekizumab-SS-1mL 320 mg (SS-s-1mL)Bimekizumab AI-1mL 320 mg (SS-a-1mL)Bimekizumab-SS-2mL 320 mg (SS-s-2mL)Bimekizumab-AI-2mL 320 mg (SS-a-2mL)Total Title
Asian22127
Black or African American22105
Native Hawaiian or Other Pacific Islander01102
White60611616153
Other or Mixed12014
08

Study locations

39 sites
  • Dv0002 946
    Phoenix, Arizona 85032, United States
  • Dv0002 910
    Bakersfield, California 93309, United States
  • Dv0002 955
    San Diego, California 92123, United States
  • Dv0002 943
    San Luis Obispo, California 93405, United States
  • Dv0002 967
    Santa Monica, California 90404, United States
  • Dv0002 906
    Boca Raton, Florida 33486, United States
  • Dv0002 907
    Miami, Florida 33144, United States
  • Dv0002 903
    Ocala, Florida 34471, United States
  • Dv0002 936
    Tampa, Florida 33624, United States
  • Dv0002 941
    Alpharetta, Georgia 30022, United States
  • Dv0002 954
    Skokie, Illinois 60077, United States
  • Dv0002 900
    West Des Moines, Iowa 50265, United States
  • Dv0002 905
    Overland Park, Kansas 66215, United States
  • Dv0002 962
    Owensboro, Kentucky 42301, United States
  • Dv0002 922
    Baton Rouge, Louisiana 70809, United States
  • Dv0002 925
    Brighton, Massachusetts 02135, United States
  • Dv0002 917
    Troy, Michigan 48084, United States
  • Dv0002 915
    St Louis, Missouri 63117, United States
  • Dv0002 901
    Portsmouth, New Hampshire 03801, United States
  • Dv0002 908
    East Windsor, New Jersey 08520, United States
  • Dv0002 913
    New York, New York 10029, United States
  • Dv0002 963
    Rochester, New York 14623, United States
  • Dv0002 920
    Portland, Oregon 97210, United States
  • Dv0002 929
    Portland, Oregon 97223, United States
  • Dv0002 937
    Johnston, Rhode Island 02919, United States
  • Dv0002 951
    Houston, Texas 77598, United States
  • Dv0002 914
    San Antonio, Texas 78213, United States
  • Dv0002 672
    Edmonton, Canada
  • Dv0002 673
    Halifax, Canada
  • Dv0002 671
    Hamilton, Canada
  • Dv0002 675
    Markham, Canada
  • Dv0002 663
    Mississauga, Canada
  • Dv0002 660
    Montreal, Canada
  • Dv0002 665
    Québec, Canada
  • Dv0002 651
    Richmond Hill, Canada
  • Dv0002 653
    Toronto, Canada
  • Dv0002 662
    Toronto, Canada
  • Dv0002 657
    Waterloo, Canada
  • Dv0002 670
    Windsor, Canada
09

References and documents

Publications

  • Sebastian M, Bagel J, Hoepken B, Knapp B, Bicer C, MacPherson M, Langley RG. Single-Injection Options for Administering a 320 mg Dose of Bimekizumab: 2 mL Safety Syringe and Auto-injector. Dermatol Ther (Heidelb). 2025 May;15(5):1113-1134. doi: 10.1007/s13555-025-01366-6. Epub 2025 Mar 29. PubMed 40156698 ↗
  • Bagel J, Tatla D, Hellot S, Knapp B, Murphy C, Peterson L, Sebastian M. Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis. J Drugs Dermatol. 2022 Feb 1;21(2):162-171. doi: 10.36849/jdd.6274. PubMed 35133113 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jul 2020, 18 months.

Results were first posted in Aug 2023, 3 years after primary completion. A results delay was requested in Jun 2021.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 18 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2018
First posted
Dec 6, 2018
StartActual
Dec 20, 2018
Primary completionActual
Jul 14, 2020
CompletionActual
Sep 8, 2020
Results delay requested
Jun 14, 2021
Results first posted
Aug 8, 2023
Last update
Jul 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03766685
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Dec 6, 2018
Start date
Dec 20, 2018
Primary completion
Jul 14, 2020
Completion
Sep 8, 2020
Results posted
Aug 8, 2023
Last update
Jul 14, 2025

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion